Literature DB >> 12533511

Proapoptotic BID is required for myeloid homeostasis and tumor suppression.

Sandra S Zinkel1, Christy C Ong, David O Ferguson, Hiromi Iwasaki, Koichi Akashi, Roderick T Bronson, Jeffery L Kutok, Frederick W Alt, Stanley J Korsmeyer.   

Abstract

The proper expansion and contraction of hematopoietic cells requires tight regulation of cell death. BID, a "BH3-only" molecule, amplifies death receptor signals connecting the extrinsic to intrinsic pathways by triggering the mitochondrial pathway of apoptosis. Bid-deficient mice, as they age, spontaneously develop a myeloproliferative disorder, which progresses from myeloid hyperplasia to a fatal, clonal malignancy closely resembling chronic myelomonocytic leukemia (CMML). Thus, an apoptotic defect can result in myeloid leukemogenesis. Premalignant Bid-/- myeloid precursor cells are resistant to death receptor-induced apoptosis. Furthermore, a competitive reconstitution assay demonstrates that Bid-deficient long-term repopulating cells give rise to expanded myelomonocytic cells in vivo. Surprisingly, a single BH3-only molecule operating in the extrinsic death receptor pathway proved essential in vivo for physiologic cell death required to maintain myeloid homeostasis. Moreover, progression to CMML indicates that an upstream BH3-only molecule, BID, is required to suppress tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12533511      PMCID: PMC195974          DOI: 10.1101/gad.1045603

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  45 in total

1.  Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML.

Authors:  K Deguchi; D G Gilliland
Journal:  Leukemia       Date:  2002-04       Impact factor: 11.528

2.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

Authors:  Anthony Letai; Michael C Bassik; Loren D Walensky; Mia D Sorcinelli; Solly Weiler; Stanley J Korsmeyer
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

3.  Limiting dilution assays. Experimental design and statistical analysis.

Authors:  L W Strijbosch; W A Buurman; R J Does; P H Zinken; G Groenewegen
Journal:  J Immunol Methods       Date:  1987-02-26       Impact factor: 2.303

Review 4.  Cellular oncogenes and multistep carcinogenesis.

Authors:  H Land; L F Parada; R A Weinberg
Journal:  Science       Date:  1983-11-18       Impact factor: 47.728

5.  BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis.

Authors:  E H Cheng; M C Wei; S Weiler; R A Flavell; T W Mak; T Lindsten; S J Korsmeyer
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

6.  Increased fetal and extramedullary hematopoiesis in Fas-deficient C57BL/6-lpr/lpr mice.

Authors:  E Schneider; G Moreau; A Arnould; F Vasseur; N Khodabaccus; M Dy; S Ezine
Journal:  Blood       Date:  1999-10-15       Impact factor: 22.113

7.  BAX and BAK mediate p53-independent suppression of tumorigenesis.

Authors:  Kurt Degenhardt; Guanghua Chen; Tullia Lindsten; Eileen White
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

8.  c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway.

Authors:  Juha Klefstrom; Emmy W Verschuren; Gerard Evan
Journal:  J Biol Chem       Date:  2002-08-28       Impact factor: 5.157

9.  Dissecting p53 tumor suppressor functions in vivo.

Authors:  Clemens A Schmitt; Jordan S Fridman; Meng Yang; Eugene Baranov; Robert M Hoffman; Scott W Lowe
Journal:  Cancer Cell       Date:  2002-04       Impact factor: 31.743

Review 10.  Genetics of myeloid leukemias.

Authors:  Louise M Kelly; D Gary Gilliland
Journal:  Annu Rev Genomics Hum Genet       Date:  2002-04-15       Impact factor: 8.929

View more
  58 in total

1.  Bad-deficient mice develop diffuse large B cell lymphoma.

Authors:  Ann M Ranger; Jiping Zha; Hisashi Harada; Sandeep Robert Datta; Nika N Danial; Andrew P Gilmore; Jeffery L Kutok; Michelle M Le Beau; Michael E Greenberg; Stanley J Korsmeyer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-22       Impact factor: 11.205

2.  Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases.

Authors:  Arndt Vogel; Joseph E Aslan; Holger Willenbring; Christian Klein; Milton Finegold; Howard Mount; Gary Thomas; Markus Grompe
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

3.  CD4 T cell-induced, bid-dependent apoptosis of cutaneous dendritic cells regulates T cell expansion and immune responses.

Authors:  Sanjay Pradhan; Joseph Genebriera; Warren L Denning; Kumar Felix; Craig A Elmets; Laura Timares
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

4.  Regulation of lymphocyte progenitor survival by the proapoptotic activities of Bim and Bid.

Authors:  Malay Mandal; Kelly M Crusio; Fanyong Meng; Suqing Liu; Marcus Kinsella; Marcus R Clark; Osamu Takeuchi; Iannis Aifantis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-16       Impact factor: 11.205

5.  Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function.

Authors:  Desiree A Steimer; Kelli Boyd; Osamu Takeuchi; Jill K Fisher; Gerard P Zambetti; Joseph T Opferman
Journal:  Blood       Date:  2008-12-08       Impact factor: 22.113

6.  Bid-ding for mercy: twisted killer in action.

Authors:  A Egle; D Asslaber; A Villunger; J Pinon-Hofbauer
Journal:  Cell Death Differ       Date:  2013-07       Impact factor: 15.828

7.  Hepatocyte-specific Bid depletion reduces tumor development by suppressing inflammation-related compensatory proliferation.

Authors:  A Wree; C D Johnson; J Font-Burgada; A Eguchi; D Povero; M Karin; A E Feldstein
Journal:  Cell Death Differ       Date:  2015-04-24       Impact factor: 15.828

8.  Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma.

Authors:  R K Lindemann; A Newbold; K F Whitecross; L A Cluse; A J Frew; L Ellis; S Williams; A P Wiegmans; A E Dear; C L Scott; M Pellegrini; A Wei; V M Richon; Paul A Marks; S W Lowe; M J Smyth; R W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-30       Impact factor: 11.205

9.  Bim is a suppressor of Myc-induced mouse B cell leukemia.

Authors:  Alexander Egle; Alan W Harris; Philippe Bouillet; Suzanne Cory
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

Review 10.  Rejuvenating Bi(d)ology.

Authors:  S S Zinkel; X M Yin; A Gross
Journal:  Oncogene       Date:  2012-10-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.